Home » Topics » BioWorld Science, Hematologic

BioWorld Science, Hematologic
RSS

Nycomed suspends development of anticlotting agent

Nov. 8, 1996

Cor Therapeutics' fibrinogen receptor antagonist effective in unstable angina

Nov. 8, 1996

Orally active antithrombotic RGD-mimetics reported by E. Merck

Nov. 8, 1996

Fujisawa claims fibrinogen antagonists

Nov. 8, 1996

Canadian researchers claim hirudin derivative

Nov. 8, 1996

Factor Xa/thrombin inhibitors from Roche

Nov. 1, 1996

Berlex discloses factor Xa inhibitors

Nov. 1, 1996

Transgenic ATIII proven safe in healthy volunteers

Oct. 25, 1996

Promising preliminary phase II results for argatroban in acute MI

Oct. 25, 1996

Servier selects TxA2 antagonist for further study

Oct. 18, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...